Ozurdex is a brand name of dexamethasone ophthalmic, approved by the FDA in the following formulation(s):
OZURDEX (dexamethasone - implant; intravitreal)
Manufacturer: ALLERGAN
Approval date: June 17, 2009
Strength(s): 0.7MG [RLD]
Has a generic version of Ozurdex been approved?
No. There is currently no therapeutically equivalent version of Ozurdex available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ozurdex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Methods for treating inflammation-mediated conditions of the eye
Patent 6,726,918
Issued: April 27, 2004
Inventor(s): Vernon G.; Wong & Mae W. L.; Hu
Assignee(s): Oculex Pharmaceuticals, Inc.
Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 &mgr;g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 &mgr;g/ml dexamethasone for at least about three weeks.Patent expiration dates:
- October 20, 2020✓✓
- October 20, 2020✓✓
- October 20, 2020
Methods and apparatus for delivery of ocular implants
Patent 6,899,717
Issued: May 31, 2005
Inventor(s): Weber; David & Kane; Ingrid & Rehal; Mike & Lathrop, III; Robert L. & Aptekarev; Kenny
Assignee(s): Allergan, Inc.
An apparatus and methods for delivering ocular implants or microimplants. The apparatus is ergonomically designed for ease of use, and a simple manual depression of an actuator produces proportional movement of a linkage causing the implant or microimplant to be ejected through a cannula disposed at the desired location in the eye. Small gauge cannulas are provided for self-sealing methods of delivery.Patent expiration dates:
- November 1, 2023✓
- November 1, 2023
Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
Patent 7,033,605
Issued: April 25, 2006
Inventor(s): Wong; Vernon G.
Assignee(s): Allergan, Inc.
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.Patent expiration dates:
- October 20, 2020✓
- October 20, 2020
Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
Patent 7,767,223
Issued: August 3, 2010
Inventor(s): Wong; Vernon G.
Assignee(s): Allergan, Inc.
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.Patent expiration dates:
- November 28, 2021✓
- November 28, 2021
Ocular implant made by a double extrusion process
Patent 8,034,366
Issued: October 11, 2011
Inventor(s): Shiah; Jane-Guo & Bhagat; Rahul & Blanda; Wendy M. & Nivaggioli; Thierry & Peng; Lin & Chou; David & Weber; David A.
Assignee(s): Allergan, Inc.
The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.Patent expiration dates:
- January 9, 2023✓✓
- January 9, 2023✓✓
- January 9, 2023
Ocular implant made by a double extrusion process
Patent 8,034,370
Issued: October 11, 2011
Inventor(s): Shiah; Jane-Guo & Bhagat; Rahul & Blanda; Wendy M. & Nivaggioli; Thierry & Peng; Lin & Chou; David & Weber; David A.
Assignee(s): Allergan, Inc.
The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.Patent expiration dates:
- January 9, 2023✓
- January 9, 2023
Methods for reducing edema
Patent 8,043,628
Issued: October 25, 2011
Inventor(s): Wong; Vernon G.
Assignee(s): Allergan, Inc.
Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.Patent expiration dates:
- October 20, 2020✓✓
- October 20, 2020
Implants and methods for treating inflammation-mediated conditions of the eye
Patent 8,063,031
Issued: November 22, 2011
Inventor(s): Wong; Vernon G. & Hu; Mae W. L.
Assignee(s): Allergan, Inc.
Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.Patent expiration dates:
- October 20, 2020✓
- October 20, 2020
Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
Patent 8,088,407
Issued: January 3, 2012
Inventor(s): Wong; Vernon G
Assignee(s): Allergan, Inc.
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.Patent expiration dates:
- October 20, 2020✓✓
- October 20, 2020
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- June 17, 2012 - NEW DOSAGE FORM
- September 24, 2017 - ORPHAN DRUG EXCLUSIVITY
See also...
- Ozurdex Consumer Information (Drugs.com)
- Ozurdex Consumer Information (Cerner Multum)
- Ozurdex Advanced Consumer Information (Micromedex)
- Dexamethasone Drops Consumer Information (Wolters Kluwer)
- Dexamethasone Suspension Consumer Information (Wolters Kluwer)
- Dexamethasone intravitreal implant Consumer Information (Cerner Multum)
- Dexamethasone ophthalmic Consumer Information (Cerner Multum)
- Dexamethasone Intraocular Advanced Consumer Information (Micromedex)
No comments:
Post a Comment